Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?

Background Currently, there is no consensus regarding which patients with high-risk prostate cancer (PCa) would benefit the most by radical prostatectomy (RP). We aimed to identify patients with high-risk PCa who are treatable by RP alone. Methods We retrospectively reviewed data on 315 patients wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical oncology 2018-08, Vol.23 (4), p.757-764
Hauptverfasser: Nagao, Kazuhiro, Matsuyama, Hideyasu, Matsumoto, Hiroaki, Nasu, Takahito, Yamamoto, Mitsutaka, Kamiryo, Yoriaki, Baba, Yoshikazu, Suga, Akinobu, Tei, Yasuhide, Yoshihiro, Satoru, Aoki, Akihiko, Shimabukuro, Tomoyuki, Joko, Keiji, Sakano, Shigeru, Takai, Kimio, Yamaguchi, Shiro, Akao, Jumpei, Kitahara, Seiji
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Currently, there is no consensus regarding which patients with high-risk prostate cancer (PCa) would benefit the most by radical prostatectomy (RP). We aimed to identify patients with high-risk PCa who are treatable by RP alone. Methods We retrospectively reviewed data on 315 patients with D’Amico high-risk PCa who were treated using RP without neoadjuvant or adjuvant therapy at the institutions of the Yamaguchi Uro-Oncology Group between 2009 and 2013. The primary endpoint was biochemical progression-free survival (bPFS) after RP. Risk factors for biochemical progression were extracted using the Cox proportional hazard model. We stratified the patients with high-risk PCa into 3 subgroups based on bPFS after RP using the risk factors. Results At a median follow-up of 49.9 months, biochemical progression was observed in 20.5% of the patients. The 2- and 5-year bPFS after RP were 89.4 and 70.0%, respectively. On multivariate analysis, Gleason score (GS) at biopsy (≥ 8, HR 1.92, p  
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-018-1272-9